In this issue:
PET-guided omission of RT in early-stage unfavourable HL
Predicting outcomes in CLL treated with ibrutinib
Risk stratification in DLBCL using lesion dissemination and metabolic tumour burden
MTHFR C677T polymorphism and high-dose MTX-related toxicity in primary CNS DLBCL
MATRix–RICE therapy and auto HSCT in DLBCL with secondary CNS involvement
A fixed-duration, MRD–guided approach in CLL
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated MCL
First-line venetoclax + R-CHOP in DLBCL
R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL
Addition of lenalidomide to intensive treatment in newly diagnosed AML
Please login below to download this issue (PDF)